Stem cell library screen identified ruxolitinib as regulator of osteoblastic differentiation of human skeletal stem cells.

Nihal AlMuraikhiDalia AliAliah AlshanwaniRadhakrishnan VishnubalajiMuthurangan ManikandanMuhammad AtteyaAbdulaziz SiyalMusaad AlfayezAbdullah AldahmashMoustapha KassemNehad M Alajez

Published in: Stem cell research & therapy (2018)

We identified ruxolitinib as an important regulator of osteoblast differentiation of hMSCs. It is plausible that inhibition of osteoblast differentiation by ruxolitinib may represent a novel therapeutic strategy for the treatment of pathological conditions caused by accelerated osteoblast differentiation and mineralization.

Keyphrases

stem cells
endothelial cells
transcription factor
bone regeneration
high throughput
cell therapy
angiotensin ii
combination therapy
induced pluripotent stem cells